Spots Global Cancer Trial Database for balstilimab
Every month we try and update this database with for balstilimab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients | NCT05363709 | HPV Oropharyngeal C... | Balstilimab | 18 Years - | M.D. Anderson Cancer Center | |
| Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas | NCT06346197 | Gastric Cancer MSI-H Metastatic Canc... Advanced Cancer | Balstilimab Botensilimab Folfox Protocol XELOX Nivolumab | 18 Years - | Centre Leon Berard | |
| A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer | NCT05033132 | Cervical Cancer | Balstilimab Balstilimab + Z... | 18 Years - | Agenus Inc. | |
| Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001) | NCT05891821 | Lymphoma | Balstilimab | 18 Years - | Immune Oncology Research Institute | |
| KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer | NCT06411691 | Colorectal Canc... Pancreatic Canc... | KRAS Vaccine wi... Balstilimab Botensilimab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG | NCT04943848 | Diffuse Intrins... Diffuse Midline... | rHSC-DIPGVax Balstilimab Zalifrelimab | 12 Months - 18 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma | NCT05864534 | Newly Diagnosed... Glioblastoma, I... Gliosarcoma Glioblastoma Mu... | Balstilimab Botensilimab Liposomal Doxor... Sonocloud-9 (SC... | 18 Years - | Northwestern University | |
| A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients | NCT05205330 | Refractory Meta... Solid Tumor Metastatic Micr... Mismatch Repair... | CR6086 AGEN2034 | 18 Years - | Rottapharm Biotech | |
| Botensilimab and Balstilimab Optimization in Colorectal Cancer | NCT06268015 | Colorectal Canc... | Botensilimab Balstilimab Oxaliplatin Leucovorin Fluorouracil Bevacizumab Panitumumab | 18 Years - | Duke University | |
| A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer | NCT06251973 | Metastatic Esop... Advanced Unrese... Metastatic Gast... Metastatic Gast... Metastatic Esop... Metastatic Esop... Metastatic Gast... Metastatic Gast... Unresectable Es... Unresectable Es... Unresectable Ga... Unresectable Ga... Unresectable Ga... | AgenT-797 Botensilimab Balstilimab Ramucirumab Paclitaxel | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations | NCT06279130 | Resectable MMR-... Resectable MMR-... | botensilimab balstilimab | 18 Years - | The Netherlands Cancer Institute | |
| Study of OBT076 Associated or Not in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck | NCT05930951 | Adenoid Cystic ... | OBT076 Balstilimab | 18 Years - | Groupe Oncologie Radiotherapie Tete et Cou | |
| A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients | NCT05561491 | Melanoma | ONCOS-102 Balstilimab | 18 Years - | Targovax ASA | |
| Study of AGEN1571 in Participants With Advanced Solid Tumors | NCT05377528 | Advanced Solid ... | AGEN1571 Balstilimab Botensilimab | 18 Years - | Agenus Inc. | |
| A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients | NCT05561491 | Melanoma | ONCOS-102 Balstilimab | 18 Years - | Targovax ASA | |
| Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial | NCT05928806 | Advanced Renal ... | Botensilimab Balstilimab Ipilimumab Nivolumab | 18 Years - | Hoosier Cancer Research Network | |
| A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | NCT05608044 | Metastatic Colo... | Botensilimab Balstilimab Standard of Car... | 18 Years - | Agenus Inc. | |
| The Seven Trial: Exploiting the Unfolded Protein Response | NCT06076837 | Pancreatic Canc... Pancreatic Aden... | Botensilimab Balstilimab Chloroquine Pho... Celecoxib | 18 Years - | HonorHealth Research Institute | |
| Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer | NCT06336902 | Metastatic Colo... Stage IV Colore... | Balstilimab Biospecimen Col... Botensilimab Computed Tomogr... Dietary Interve... Magnetic Resona... Vitamin C | 18 Years - | University of Southern California | |
| A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | NCT05608044 | Metastatic Colo... | Botensilimab Balstilimab Standard of Car... | 18 Years - | Agenus Inc. | |
| Combination Immunotherapy in Colorectal Cancer | NCT05571293 | Colorectal Neop... | Botensilimab Balstilimab | 18 Years - | Weill Medical College of Cornell University | |
| Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | NCT03860272 | Advanced Cancer Angiosarcoma Colorectal Canc... Endometrial Can... Fibrolamellar C... Non-small-cell ... Ovarian Cancer Prostate Cancer | Botensilimab Balstilimab | 18 Years - | Agenus Inc. | |
| Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer | NCT05638698 | Pancreas Cancer | TG01 Vaccine QS-21 Balstilimab | 18 Years - | University of Kansas Medical Center | |
| Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884) | NCT05572970 | Cancer | Balstilimab Zalifrelimab | 18 Years - | Agenus Inc. | |
| Botensilimab and Balstilimab Optimization in Colorectal Cancer | NCT06268015 | Colorectal Canc... | Botensilimab Balstilimab Oxaliplatin Leucovorin Fluorouracil Bevacizumab Panitumumab | 18 Years - | Duke University | |
| The Seven Trial: Exploiting the Unfolded Protein Response | NCT06076837 | Pancreatic Canc... Pancreatic Aden... | Botensilimab Balstilimab Chloroquine Pho... Celecoxib | 18 Years - | HonorHealth Research Institute | |
| AGEN1423 Plus Balstilimab With or Without Chemo in Pancreatic Cancer | NCT05632328 | Advanced Pancre... Pancreatic Duct... Pancreatic Canc... | AGEN1423 Balstilimab Gemcitabine Nab-paclitaxel | 18 Years - | Beth Israel Deaconess Medical Center | |
| AGEN1423 Plus Balstilimab With or Without Chemo in Pancreatic Cancer | NCT05632328 | Advanced Pancre... Pancreatic Duct... Pancreatic Canc... | AGEN1423 Balstilimab Gemcitabine Nab-paclitaxel | 18 Years - | Beth Israel Deaconess Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
